Frontiers in Immunology · 2019 · 78 citations · 38 references
MedicineCancer BiologyOncologyAntibody EngineeringImmunotherapyMolecular OncologyBispecific AntibodiesBispecific Antibody TherapyCancer ImmunotherapyImmunotherapy For Breast CancerImmunotherapy For Solid TumorsTargeted Cancer TherapyAntibody-dependent Cell-mediated CytotoxicityBispecific Antibody ConjugatesBispecific Antibody DiscoveryBispecific Antibody FormatsBispecific Antibody FragmentsBispecific Antibody SelectionTriple-negative Breast Cancer ImmunotherapyTumor Cell Invasiveness
Triple negative breast cancers (TNBC) remain a major medical challenge due to poor prognosis and limited treatment options. Mesothelin is a glycosyl-phosphatidyl inositol-linked membrane protein with restricted normal expression and high level expression in a large proportion of TNBC, thus qualifying as an attractive target. Its overexpression in breast tumors has been recently correlated with a decreased disease-free survival and an increase of distant metastases. The objective of the study was to investigate the relevance of a bispecific antibody-based immunotherapy approach through mesothelin targeting and CD16 engagement using a Fab-like bispecific format (MesobsFab). Using two TNBC cell lines with different level of surface mesothelin and epithelial/mesenchymal phenotypes, we showed that in vitro MesobsFab promotes the recruitment and penetration of effector cells into tumor spheroids, induces potent dose-dependent cell-mediated cytotoxicity of mesothelin-positive tumor cells, cytokine secretion and decreases cell invasiveness. In vivo, the anti-tumor effect of MesobsFab depends upon a threshold of MSLN density on target cells. Collectively our data support mesothelin as a relevant therapeutic target for the subset of TNBC that overexpresses mesothelin characterized by a low overall and disease-free survival as well as the potential of MesobsFab as antibody-based immunotherapeutics.
38
Spheroid-based drug screen: considerations and practical approach
Juergen Friedrich, Claudia Seidel, Reinhard Ebner et al. · Nature Protocols · 2009 · 1.7K citations
Regulation of human NK-cell cytokine and chemokine production by target cell recognition
Cyril Fauriat, Eric O. Long, Hans‐Gustaf Ljunggren et al. · Blood · 2009 · 843 citations · Full text